208 related articles for article (PubMed ID: 24821006)
1. Thyroid dysfunctions induced by tyrosine kinase inhibitors.
Fallahi P; Ferrari SM; Vita R; Di Domenicantonio A; Corrado A; Benvenga S; Antonelli A
Expert Opin Drug Saf; 2014 Jun; 13(6):723-33. PubMed ID: 24821006
[TBL] [Abstract][Full Text] [Related]
2. Endocrine side-effects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors.
Illouz F; Braun D; Briet C; Schweizer U; Rodien P
Eur J Endocrinol; 2014 Sep; 171(3):R91-9. PubMed ID: 24833135
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders.
Jannin A; Penel N; Ladsous M; Vantyghem MC; Do Cao C
Crit Rev Oncol Hematol; 2019 Sep; 141():23-35. PubMed ID: 31202955
[TBL] [Abstract][Full Text] [Related]
4. Endocrine-related adverse conditions induced by tyrosine kinase inhibitors.
De Leo S; Trevisan M; Moneta C; Colombo C
Ann Endocrinol (Paris); 2023 May; 84(3):374-381. PubMed ID: 36963756
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management.
Brown RL
Target Oncol; 2011 Dec; 6(4):217-26. PubMed ID: 22101606
[TBL] [Abstract][Full Text] [Related]
6. Cardiotoxicity induced by tyrosine kinase inhibitors.
Orphanos GS; Ioannidis GN; Ardavanis AG
Acta Oncol; 2009; 48(7):964-70. PubMed ID: 19734999
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
Di Gion P; Kanefendt F; Lindauer A; Scheffler M; Doroshyenko O; Fuhr U; Wolf J; Jaehde U
Clin Pharmacokinet; 2011 Sep; 50(9):551-603. PubMed ID: 21827214
[TBL] [Abstract][Full Text] [Related]
8. Expert opinion on thyroid complications of new anti-cancer therapies: Tyrosine kinase inhibitors.
Drui D; Illouz F; Do Cao C; Caron P
Ann Endocrinol (Paris); 2018 Oct; 79(5):569-573. PubMed ID: 30126626
[TBL] [Abstract][Full Text] [Related]
9. Major adverse cardiovascular events of vascular endothelial growth factor tyrosine kinase inhibitors among patients with different malignancy: A systemic review and network meta-analysis.
Chen YC; Chen JH; Hsieh FI
J Chin Med Assoc; 2024 Jan; 87(1):48-57. PubMed ID: 37991373
[TBL] [Abstract][Full Text] [Related]
10. Thyroid dysfunction as an unintended side effect of anticancer drugs.
Torino F; Barnabei A; Paragliola R; Baldelli R; Appetecchia M; Corsello SM
Thyroid; 2013 Nov; 23(11):1345-66. PubMed ID: 23750887
[TBL] [Abstract][Full Text] [Related]
11. Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma.
Bianchi L; Rossi L; Tomao F; Papa A; Zoratto F; Tomao S
Endocr Relat Cancer; 2013 Oct; 20(5):R233-45. PubMed ID: 23833016
[TBL] [Abstract][Full Text] [Related]
12. Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy.
Bronte G; Bronte E; Novo G; Pernice G; Lo Vullo F; Musso E; Bronte F; Gulotta E; Rizzo S; Rolfo C; Silvestris N; Bazan V; Novo S; Russo A
Expert Opin Drug Saf; 2015 Feb; 14(2):253-67. PubMed ID: 25494575
[TBL] [Abstract][Full Text] [Related]
13. The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function.
Tsai K; Ma H; Liang TZ; Xing Y; Chung S; Dorff T; Bell D; Lechner MG
Thyroid; 2024 Feb; 34(2):158-166. PubMed ID: 38069567
[No Abstract] [Full Text] [Related]
14. Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2014 Sep; 14(9):1063-73. PubMed ID: 24927771
[TBL] [Abstract][Full Text] [Related]
15. Therapy of endocrine disease: response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis.
Klein Hesselink EN; Steenvoorden D; Kapiteijn E; Corssmit EP; van der Horst-Schrivers AN; Lefrandt JD; Links TP; Dekkers OM
Eur J Endocrinol; 2015 May; 172(5):R215-25. PubMed ID: 25572389
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis.
Makita N; Iiri T
Thyroid; 2013 Feb; 23(2):151-9. PubMed ID: 23398161
[TBL] [Abstract][Full Text] [Related]
17. Current evidence on thyroid related adverse events in patients treated with protein tyrosine kinase inhibitors.
Gabora K; Piciu A; Bădulescu IC; Larg MI; Stoian IA; Piciu D
Drug Metab Rev; 2019 Nov; 51(4):562-569. PubMed ID: 31718371
[TBL] [Abstract][Full Text] [Related]
18. Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.
Huillard O; Boissier E; Blanchet B; Thomas-Schoemann A; Cessot A; Boudou-Rouquette P; Durand JP; Coriat R; Giroux J; Alexandre J; Vidal M; Goldwasser F
Expert Opin Drug Saf; 2014 May; 13(5):663-73. PubMed ID: 24693873
[TBL] [Abstract][Full Text] [Related]
19. Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients.
Resteghini C; Cavalieri S; Galbiati D; Granata R; Alfieri S; Bergamini C; Bossi P; Licitra L; Locati LD
Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):349-361. PubMed ID: 28911730
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use.
Dasanu CA; Padmanabhan P; Clark BA; Do C
Expert Opin Drug Saf; 2012 May; 11(3):445-57. PubMed ID: 22469002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
